首页> 美国卫生研究院文献>ISRN Nephrology >Effect of N-Acetylcysteine on Residual Renal Function in Chronic Haemodialysis Patients Treated with High-Flux Synthetic Dialysis Membranes: A Pilot Study
【2h】

Effect of N-Acetylcysteine on Residual Renal Function in Chronic Haemodialysis Patients Treated with High-Flux Synthetic Dialysis Membranes: A Pilot Study

机译:N-乙酰半胱氨酸对高通量合成透析膜治疗的慢性血液透析患者残余肾功能的影响:一项初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Preservation of residual renal function in chronic dialysis patients has proven to be a major predictor of survival. The aim of the present study was to investigate an ability of the combined use of N-acetylcysteine and high-flux biocompatible haemodialysis membranes to improve residual renal function in haemodialysis patients. Patients and Methods. Chronic haemodialysis patients with a residual urine output of at least 100 mL/24 h were administered oral an N-acetylcysteine 1200 mg twice daily for 2 weeks. Treatment group included patients treated with dialysers using high-flux synthetic biocompatible membranes. Control group included patients treated with dialysers using low-flux semisyntetic triacetate haemodialysis membranes. Results. Eighteen patients participated in the study. The residual glomerular filtration rate showed a nonsignificant trend for increase in both groups. The magnitude of GFR improvement after N-acetylcysteine administration was less pronounced in the group treated with high-flux biocompatible membranes: +0.17 ± 0.56 mL/min/1.73 m2 in treatment group and +0.65 ± 0.53 mL/min/1.73 m2 in control group (P < 0.05). Conclusion. In this study of favorable effect of N-acetylcysteine on residual renal function in chronic haemodialysis patients may be less pronounced when using high-flux biocompatible, rather than low-flux semisyntetic, HD membranes.
机译:背景。慢性透析患者中​​残余肾功能的保留已被证明是生存的主要预测指标。本研究的目的是研究结合使用N-乙酰半胱氨酸和高通量生物相容性血液透析膜来改善血液透析患者的残余肾功能的能力。患者和方法。残余尿量至少为100µmL / 24µh的慢性血液透析患者,每天两次口服N-乙酰半胱氨酸1200µmg,持续2周。治疗组包括使用高通量生物相容性合成膜透析器治疗的患者。对照组包括使用低通量半syntsyct三乙酸酯血液透析膜进行透析治疗的患者。结果。 18名患者参加了该研究。两组的残余肾小球滤过率均无明显增加趋势。高通量生物相容性膜治疗组中N-乙酰半胱氨酸给药后GFR改善的程度较不明显:治疗组为+0.17±0.56 0.5mL / min / 1.73 m 2 ,+ 0.65±0.53对照组为mL / min / 1.73 m 2 (P <0.05)。结论。在这项研究中,当使用高通量生物相容性而非低通量半窦性HD膜时,N-乙酰半胱氨酸对慢性血液透析患者残余肾功能的有利作用可能不太明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号